Dr. Pinter-Brown on Treatment Expectations in CTCL

Lauren Pinter-Brown, MD
Published Online: Tuesday, April 2, 2013
Lauren Pinter-Brown, MD, Clinical Professor, Department of Medicine, Hematology-Oncology, University of California, Los Angeles, discusses physician and patient expectations when treating cutaneous T-cell lymphoma (CTCL).

As with other oncologic conditions, if a patient is being treated with a drug and progresses, it is obvious that the drug is ineffective. In patients with CTCL, physicians have to be aware of the time to response for particular treatments, as they're not identical.

In the case of bexarotene, the time to response is four months, which causes physicians and patients to set appropriate expectations as the patient's condition will not worsen but it will not get better for many months. Fortunately, monitoring CTCL does not require scans or blood tests: physicians simply have to monitor skin lesions as time passes.

Online CME Activities
Free CME from PER
B-Cell Malignancies: Novel Agents, Emerging Treatment Strategies, and the Revolution of Care
Community Practice Connections: 15th Annual International Lung Cancer CongressĀ®
Community Practice Connections: 13th Annual International Congress on the Future of Breast CancerĀ®
Highlights From the 13th Annual International Congress on the Future of Breast CancerĀ®
More Reading
$auto_registration$